Studies of BRUKINSA ® (zanubrutinib), BTK CDAC degrader BGB-16673 and BCL2 inhibitor sonrotoclax featured in invited talks and oral presentations BeiGene has seven presentations at IWWM 2024, and ...

The approval of zanubrutinib makes it just the second therapy indicated for this rare type of lymphoma. The FDA has approved zanubrutinib (Brukinsa) for the treatment of adults with Waldenström ...

The US Food and Drug Administration (FDA) has approved zanubrutinib (Brukinsa) capsules for use in the treatment of adult patients with Waldenström's macroglobulinemia (WM), a rare non-Hodgkin ...

Posters presented at the AMCP Nexus 2021 meeting reviewed the cost-effectiveness and cost per response for zanubrutinib vs ibrutinib. In patients with relapsed/refractory Waldenström macroglobulinemia ...

The approval was based on data from the phase 3 ASPEN trial. The Food and Drug Administration (FDA) has approved Brukinsa ® (zanubrutinib) for the treatment of adults with Waldenström ...

Steven P. Treon, MD, PhD: The diagnosis of Waldenström macroglobulinemia requires a couple of things. First, it requires detection of the IgM monoclonal protein. So that’s a blood test. One would also ...

NEW YORK — In the wake of details about the molecular pathophysiology of Waldenström macroglobulinemia (WM), an expert gave an update on current and expanding options for treatment. Most importantly, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The investigational targeted radiotherapy iopofosine I ...

Waldenström’s Macroglobulinemia: Clinical Features, Complications, and Management. If you have the appropriate software installed, you can download article citation data to the citation manager of ...

The Golden Bachelor’s Gerry Turner is opening up about a recent medical diagnosis. He told People that he was diagnosed with a slow-growing blood marrow cancer in early 2024. The news comes eight ...

SAN MATEO, Calif.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share research from studies evaluating BRUKINSA ® ...